Therapeutics announced the presentation of new clinical data from its ongoing Phase 2 trial with stenoparib monotherapy in ...

The Fellows of the AACR Academy have elected Elaine V. Fuchs, PhD, FAACR, as their next President. She will assume the ...

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness in patients with platinum-resistant or refractory ovarian cancer. These patients typically have ...

Recent work in The EMBO Journal describes a new hybrid post-translational modification of proteins, composed of a poly-ubiquitin chain that is attached to a target protein via a mono-ADP-ribose (MAR) ...

Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

对肿瘤侵袭性特征的影响 ：研究发现，RS-35d 单独使用可显著降低 BxPC-3 细胞集落形成率，与 olaparib 联合使用时效果更显著。在伤口愈合实验中，RS-35d/olaparib、S-35d/olaparib 和 R-35d/olaparib 组合均能显著降低细胞迁移，但 RS-35d 单独使用时也有明显效果。通过流式细胞术分析凋亡发现，RS-35d/olaparib 和 S-35d ...

Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.

Registration https://southcenters.osu.edu/horticulture/high-tunnel-workshop or call 765-973-9281. $25 Registration does not include pesticide credit fee.

截至到2025年3月11日，由Sam S Yoon作为负责人的已经被撤回包括在MOLECULAR CANCER RESEARCH，Cancer Research，CLINICAL CANCER RESEARCH 及Cell Death & ...

In cancer research, for instance, the discovery of specific oncogenes such as breast cancer susceptibility gene (BRCA) 1 and BRCA2 has directly led to the development of targeted therapies such as ...